Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | Monoclonal antibody combinations in ALL

Francesco Lanza • 17 Sep 2020
SOHO Italy 2020
Acute Lymphoblastic Leukemia Leukemia Blinatumomab CAR-T Inotuzumab ozogamicin

Francesco Lanza, MD, Ravenna Hospital, Ravenna, Italy, outlines the sequential use of novel monoclonal antibodies for the treatment of adult acute lymphoblastic leukemia (ALL) who are relapsed/refractory to chemotherapy, including blinatumomab, a CD19 targeting monoclonal antibody, as well as inotuzumab ozogamicin, an antibody-drug conjugate. Dr Lanza also discusses the sequential use of CAR T-cell based therapies in combination with monoclonal antibodies and controversy surrounding this treatment approach. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Francesco Lanza

How the AML treatment landscape is changing with the introduction of novel targeted agents
5:25
How the AML treatment landscape is changing with the introduction of novel targeted agents
Francesco Lanza • 24 Oct 2022
The importance of achieving CR before stem cell transplantation in patients with AML and ALL
1:39
The importance of achieving CR before stem cell transplantation in patients with AML and ALL
Francesco Lanza • 24 Oct 2022
Optimizing biological agents for ALL
2:42
Optimizing biological agents for ALL
Francesco Lanza • 17 Sep 2020

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals